These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 6600395)

  • 1. Clearance rates and systemic effects of intravenously administered interleukin 2 (IL-2) containing preparations in human subjects.
    Bindon C; Czerniecki M; Ruell P; Edwards A; McCarthy WH; Harris R; Hersey P
    Br J Cancer; 1983 Jan; 47(1):123-33. PubMed ID: 6600395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo administration of purified human interleukin 2. I. Half-life and immunologic effects of the Jurkat cell line-derived interleukin 2.
    Lotze MT; Frana LW; Sharrow SO; Robb RJ; Rosenberg SA
    J Immunol; 1985 Jan; 134(1):157-66. PubMed ID: 3871099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy of murine sarcomas using lymphokine activated killer cells: optimization of the schedule and route of administration of recombinant interleukin-2.
    Ettinghausen SE; Rosenberg SA
    Cancer Res; 1986 Jun; 46(6):2784-92. PubMed ID: 3486038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy of metastatic melanoma by intratumoral injections of Vero cells producing human IL-2: phase II randomized study comparing two dose levels.
    Rochlitz C; Dreno B; Jantscheff P; Cavalli F; Squiban P; Acres B; Baudin M; Escudier B; Heinzerling L; Morant R; Herrmann R; Dietrich PY; Dummer R
    Cancer Gene Ther; 2002 Mar; 9(3):289-95. PubMed ID: 11896446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2.
    Lotze MT; Matory YL; Ettinghausen SE; Rayner AA; Sharrow SO; Seipp CA; Custer MC; Rosenberg SA
    J Immunol; 1985 Oct; 135(4):2865-75. PubMed ID: 2993418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interleukin 2 (IL 2) administered in vivo: influence of IL 2 route and timing on T cell growth.
    Cheever MA; Thompson JA; Kern DE; Greenberg PD
    J Immunol; 1985 Jun; 134(6):3895-900. PubMed ID: 3872906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A mitogenic factor, released by stimulated human mononuclear cells and distinct from interleukin 2 (IL 2), B cell growth factor (BCGF), and interleukin 1 (IL 1).
    Kasakura S; Taguchi M; Watanabe Y; Okubo T; Murachi T; Uchino H; Hanaoka M
    J Immunol; 1984 Dec; 133(6):3084-90. PubMed ID: 6238094
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study.
    Goedegebuure PS; Douville LM; Li H; Richmond GC; Schoof DD; Scavone M; Eberlein TJ
    J Clin Oncol; 1995 Aug; 13(8):1939-49. PubMed ID: 7636534
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancement by interleukin 4 of interleukin 2- or antibody-induced proliferation of lymphocytes from interleukin 2-treated cancer patients.
    Treisman J; Higuchi CM; Thompson JA; Gillis S; Lindgren CG; Kern DE; Ridell SR; Greenberg PD; Fefer A
    Cancer Res; 1990 Feb; 50(4):1160-4. PubMed ID: 2153452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential uses of interleukin 2 in cancer therapy.
    Cheever MA; Thompson JA; Peace DJ; Greenberg PD
    Immunobiology; 1986 Sep; 172(3-5):365-82. PubMed ID: 3492434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful immunotherapy of natural killer-resistant established pulmonary melanoma metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin 2.
    Mazumder A; Rosenberg SA
    J Exp Med; 1984 Feb; 159(2):495-507. PubMed ID: 6141211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of route and formulation on clinical pharmacokinetics of interleukin-2.
    Anderson PM; Sorenson MA
    Clin Pharmacokinet; 1994 Jul; 27(1):19-31. PubMed ID: 7955769
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Comparative characteristics of human interleukin-2 preparations isolated from various sources].
    Iobadze MS; Kulikov VV; Kupriianova TA; Bykovskaia SN; Bakhutashvili VI
    Biokhimiia; 1986 Aug; 51(8):1341-7. PubMed ID: 3490280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative study on the effects of recombinant alpha-2 interferon on immune function in patients with disseminated melanoma.
    Hersey P; Coates A; Rallings M; Hall C; MacDonald M; Spurling A; Edwards A; McCarthy WH; Milton GW
    J Biol Response Mod; 1986 Jun; 5(3):236-49. PubMed ID: 3487622
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intralesional injection of interleukin-2-expanded autologous lymphocytes in melanoma and breast cancer patients: a pilot study.
    Adler A; Stein JA; Kedar E; Naor D; Weiss DW
    J Biol Response Mod; 1984 Oct; 3(5):491-500. PubMed ID: 6334137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I evaluation of recombinant interleukin-2 in patients with advanced malignant disease.
    Atkins MB; Gould JA; Allegretta M; Li JJ; Dempsey RA; Rudders RA; Parkinson DR; Reichlin S; Mier JW
    J Clin Oncol; 1986 Sep; 4(9):1380-91. PubMed ID: 3489080
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2.
    Rosenberg SA; Mulé JJ; Spiess PJ; Reichert CM; Schwarz SL
    J Exp Med; 1985 May; 161(5):1169-88. PubMed ID: 3886826
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The fate of interleukin-2 after in vivo administration.
    Donohue JH; Rosenberg SA
    J Immunol; 1983 May; 130(5):2203-8. PubMed ID: 6601147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficient harvest of in vivo IL-2-activated CD3+ lymphocytes for adoptive immunotherapy by selective leukapheresis (lymphocytapheresis).
    Masucci G; Svensson A; Hansson M; Hansson J; Nakazawa T; Salazar F; Petersson M; Kiessling R
    J Hematother; 1997 Jun; 6(3):253-60. PubMed ID: 9234180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low dose subcutaneous interleukin-2 after autologous transplantation generates sustained in vivo natural killer cell activity.
    Miller JS; Tessmer-Tuck J; Pierson BA; Weisdorf D; McGlave P; Blazar BR; Katsanis E; Verfaillie C; Lebkowski J; Radford J; Burns LJ
    Biol Blood Marrow Transplant; 1997 Apr; 3(1):34-44. PubMed ID: 9209739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.